Wall Street analysts forecast that Gemphire Therapeutics Inc (NASDAQ:GEMP) will announce earnings per share of ($0.39) for the current quarter, Zacks reports. Zero analysts have made estimates for Gemphire Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.37) and the lowest estimate coming in at ($0.41). Gemphire Therapeutics reported earnings of ($0.63) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 38.1%. The firm is scheduled to issue its next earnings results on Thursday, March 21st.
On average, analysts expect that Gemphire Therapeutics will report full-year earnings of ($1.89) per share for the current financial year, with EPS estimates ranging from ($1.89) to ($1.88). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.05) per share, with EPS estimates ranging from ($2.50) to ($1.59). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Gemphire Therapeutics.
Gemphire Therapeutics (NASDAQ:GEMP) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.04.
NASDAQ:GEMP opened at $1.17 on Friday. Gemphire Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $11.43. The firm has a market cap of $16.69 million, a P/E ratio of -0.36 and a beta of 2.46. The company has a debt-to-equity ratio of 0.59, a quick ratio of 3.27 and a current ratio of 3.27.
A number of hedge funds and other institutional investors have recently modified their holdings of GEMP. VHCP Management III LLC purchased a new position in shares of Gemphire Therapeutics in the third quarter worth about $1,791,000. BlackRock Inc. increased its position in shares of Gemphire Therapeutics by 2,210.5% in the third quarter. BlackRock Inc. now owns 675,038 shares of the company’s stock valued at $1,391,000 after buying an additional 645,822 shares in the last quarter. VHCP Management II LLC purchased a new stake in shares of Gemphire Therapeutics in the third quarter valued at approximately $1,058,000. Millennium Management LLC purchased a new stake in shares of Gemphire Therapeutics in the second quarter valued at approximately $1,981,000. Finally, Nomura Holdings Inc. purchased a new stake in shares of Gemphire Therapeutics in the second quarter valued at approximately $556,000. 29.20% of the stock is owned by institutional investors and hedge funds.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.
Featured Article: Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.